Evaluation of the AIVARIX in Detecting Signs C 1-2 Classes of CVD
N/A
Completed
NCT05612217
| Condition | Chronic Venous Disease, CVD |
|---|
| Phase | N/A |
|---|
| Sponsor | Servier Russia |
|---|
| Status | Completed |
|---|
| Enrollment | 433 participants |
|---|
| Interventions | to estimate Sensitivity and Specificity AIVARIX app in detecting C1 and C2 classes of CVD |
|---|
| Start date | Dec 1, 2022 |
|---|
| Completion date | Jun 1, 2023 |
|---|
| Results posted | Sep 25, 2024 |
|---|
Summary
This study is a multicenter observational study, which is carried out in frame of routine clinical practice in Russia. The program will include patients suggestive to chronic venous diseases (CVDs) including but not limited to those with C1 and C2 classes by CEAP classification, who will be seeking professional phlebologists' consultation. Study conduction is scheduled in Russia in 2022-2023. The planned number of patients is 414
Evaluation of Sensitivity (Sn) of the AI-based AIVARIX App in Detecting C1 and C2 Classes of CVD in Patients Who Are Seeking for Professional Advice From a Phlebologist Regarding Symptoms and Signs Suggestive to CVD.
1 month · percentage of of positive cases
| Patients With CVD | 75.19 percentage of of positive cases |
|---|
Evaluation of Specificity (Sp) of the AI-based AIVARIX App in Detecting C1 and C2 Classes of CVD in Patients Who Are Seeking for Professional Advice From a Phlebologist Regarding Symptoms and Signs Suggestive to CVD
1 month · percentage of negative cases
| Patients With CVD | 86.51 percentage of negative cases |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.